ストックスクリーナーアプリを入手
6.37
2.00%
-0.13
アフターアワーズ：
6.40
0.03
+0.47%
前日終値:
$6.50
開ける：
$6.5
24時間の取引高:
3.79M
Relative Volume:
0.45
時価総額：
$1.17B
収益：
$847.25M
当期純損益:
$-284.86M
株価収益率:
-2.7817
EPS:
-2.29
ネットキャッシュフロー:
$-112.35M
1週間 パフォーマンス:
-0.62%
1か月 パフォーマンス:
-13.69%
6か月 パフォーマンス:
-23.07%
1年 パフォーマンス:
-50.35%
1日の値動き範囲:
$6.31
$6.575
1週間の範囲:
$6.13
$6.66
52週間の値動き範囲:
$5.01
$17.81
Novavax Inc Stock (NVAX) Company Profile
NVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.37 | 1.17B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | BTIG Research | Buy |
| 2024-07-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-05-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-08-09 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 繰り返されました | B. Riley Securities | Buy |
| 2022-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-02 | 開始されました | Jefferies | Hold |
| 2022-09-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2022-02-22 | 再開されました | Jefferies | Buy |
| 2022-01-21 | 開始されました | Cowen | Outperform |
| 2021-05-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-05 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 繰り返されました | B. Riley FBR | Buy |
| 2020-06-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 繰り返されました | B. Riley FBR | Buy |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-08-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-28 | ダウングレード | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-11 | 開始されました | Oppenheimer | Outperform |
| 2018-11-26 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | アップグレード | JP Morgan | Underweight → Overweight |
| 2018-03-29 | アップグレード | Seaport Global Securities | Neutral → Buy |
すべてを表示
Novavax Inc (NVAX) 最新ニュース
Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus
Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus
Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK
Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus
Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
Novavax: positive results for Covid/flu vaccine - MarketScreener
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance
Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Pipelinereview
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report - Benzinga
Novavax at Goldman Sachs Healthcare Conference: Strategic Shift to R&D Focus - Investing.com Nigeria
RFK Jr. picks eight new members to CDC vaccine advisory panel - Seeking Alpha
Novavax's COVID-19-Influenza Combination and Stand-alone Influen - GuruFocus
Novavax (NVAX) Phase 3 Trial Shows Promising Results in Vaccine Study | NVAX Stock News - GuruFocus
Novavax reports positive results for COVID-19 and flu vaccine candidates By Investing.com - Investing.com South Africa
Transcript : Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com
Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates - Yahoo Finance
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Novavax's COVID-flu combo vaccine shows strong immune response in trial - Reuters
Novavax (NVAX) Reports Promising Results for COVID-19-Flu Vaccine Combo - GuruFocus
Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall By Investing.com - Investing.com Canada
Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study - marketscreener.com
Novavax stock gains on data for COVID-flu shot (NVAX:NASDAQ) - Seeking Alpha
Novavax reports positive results for COVID-19 and flu vaccine candidates - Investing.com Canada
Novavax (NVAX) Reports Positive Results for COVID-Influenza Comb - GuruFocus
Novavax Reports Promising Phase 3 Vaccine Trial Results - TipRanks
Novavax (NVAX) Reports Positive Results for COVID-Influenza Combo Vaccine Trial | NVAX Stock News - GuruFocus
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - marketscreener.com
Novavax Breakthrough: Phase 3 Trial Reveals Strong Results for First-of-Kind COVID-Flu Combo Vaccine - Stock Titan
Vaccine makers steady despite RFK Jr.'s removal of CDC expert panel (PFE:NYSE) - Seeking Alpha
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel - marketscreener.com
Vaccine Stocks Stay Steady Despite US Health Shake-Up - Finimize
Recombinant Vaccine Market is Booming Worldwide with - openPR.com
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance - Benzinga
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - MSN
RFK Jr. removing, replacing all members of CDC vaccine advisory panel (MRNA:NASDAQ) - Seeking Alpha
Where are the Opportunities in (NVAX) - news.stocktradersdaily.com
Investor Network: Novavax, Inc to Host Earnings Call - ACCESS Newswire
July 25th Options Now Available For Novavax (NVAX) - Nasdaq
LigaChem Biosciences adopts U.S. Novavax technology for next-gen ADCs - Chosunbiz
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus
RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga
Novavax to Participate in Upcoming Investor Conferences - Quantisnow
Novavax Inc (NVAX) 財務データ
収益
当期純利益
現金流量
EPS
Novavax Inc (NVAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):